Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07397936

Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract Surgery

Conditions: Dry Eye Disease (DED), Cataract

Sex: All
Ages: 40 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 56
Sponsor: Samsung Medical Center

Location: Samsung Medical Center Seoul Seoul

Summary

The goal of this clinical trial is to compare the efficacy of 2% rebamipide monotherapy versus a combination therapy of 3% diquafosol and 0.05% cyclosporine for the management of dry eye disease in patients undergoing cataract surgery. It will also evaluate the safety and ocular surface stability effects of these treatments during the perioperative period. The main questions it aims to answer are: Does rebamipide monotherapy maintain tear film breakup time (TBUT) and prevent corneal damage as effectively as the combination therapy after surgery? How do patient symptoms (OSDI scores) and inflammation markers (MMP-9) change with each treatment? Researchers will compare the rebamipide group to the diquafosol-cyclosporine combination group to evaluate their effects on perioperative dry eye management. Participants will: Use the assigned study eye drops starting 1 month before their cataract surgery and continuing for 3 months after surgery. Visit the clinic for eye examinations at baseline, the day of surgery, and at 1 week, 1 month, and 3 months postoperatively. Undergo tests including tear film breakup time measurement, corneal staining, Schirmer's test, and tear MMP-9 level assessments.

Eligibility Criteria

Inclusion Criteria: * Adults scheduled for cataract surgery * Presence of dry eye disease, defined as an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following: * Tear film breakup time (TBUT) ≤7 seconds * Oxford corneal staining grade ≥1 * Schirmer's test value ≤10 mm/5 min * Ability and willingness to comply with the study protocol and follow-up schedule * Provision of written informed consent Exclusion Criteria: * Presence of ocular surface or ocular conditions that could affect dry eye status (e.g., active keratitis or ocular infection) * Use of topical intraocular pressure-lowering medications * History of ocular surgery other than cataract surgery in the study eye * Any systemic or ocular condition judged by the investigator to interfere with study participation or outcome assessment

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07397936). StuddyBuddy aggregates publicly available trial information.